Supernus Pharmaceuticals (SUPN) : The most positive equity analysts on Supernus Pharmaceuticals (SUPN) expects the shares to touch $37, whereas, the least positive believes that the stock will trade at $24 in the short term. The company is covered by 6 Wall Street Brokerage Firms. The average price target for shares are $27.67 with an expected fluctuation of $4.84 from the mean.
Supernus Pharmaceuticals (SUPN) : 6 analysts are covering Supernus Pharmaceuticals (SUPN) and their average rating on the stock is 1.67, which is read as a Buy. 4 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 2 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Also, Jefferies maintains its rating on Supernus Pharmaceuticals (NASDAQ:SUPN). The global brokerage major raises the current price target from $23 per share to $28 per share. Analysts at the Jefferies have a current rating of Buy on the shares. The rating by the firm was issued on August 4, 2016.
Supernus Pharmaceuticals (NASDAQ:SUPN): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $21.47 and $21.37 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $22.12. The buying momentum continued till the end and the stock did not give up its gains. It closed at $22.03, notching a gain of 3.04% for the day. The total traded volume was 490,556 . The stock had closed at $21.38 on the previous day.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing products for the treatment of central nervous system diseases. The Company launched its two products in neurology for the treatment of epilepsy, which include Oxtellar XR and Trokendi XR. It is also engaged in developing multiple product candidates in psychiatry to address the medical needs and market opportunities in impulsive aggression across several areas (such as attention deficit hyperactivity disorder (ADHD), autism and bipolar disorder), and ADHD. The Company markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which are indicated for epilepsy in the United States. Its product candidates include Oxtellar XR, Trokendi XR, SPN-810, SPN-812 and SPN-809.